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Objective: The aim of the present study is to investigate the effect of antioxidant polyphenol-rich pomegranate juice (PJ)
supplementation for 5 weeks on patients with stable chronic obstructive pulmonary disease (COPD), since the oxidative stress
plays a major role in the evolution and pathophysiology of COPD.
Design: A randomized, double-blind, placebo-controlled trial was conducted.
Subjects: A total of 30 patients with stable COPD were randomly distributed in two groups (15 patients each).
Interventions: Both groups consumed either 400 ml PJ daily or matched placebo (synthetic orange-flavoured drink) for 5 weeks.
Trolox Equivalent Antioxidant Capacity (TEAC) of PJ, blood parameters (14 haematological and 18 serobiochemical), respiratory
function variables, bioavailability of PJ polyphenols (plasma and urine) and urinary isoprostane (8-iso-PGF2a) were evaluated.
Results: The daily dose of PJ (containing 2.66 g polyphenols) provided 4 mmol/l TEAC. None of the polyphenols present in PJ
were detected in plasma or in urine of volunteers. The most abundant PJ polyphenols, ellagitannins, were metabolized by the
colonic microflora of COPD patients to yield two major metabolites in both plasma and urine (dibenzopyranone derivatives)
with no TEAC. No differences were found (P40.05) between PJ and placebo groups for any of the parameters evaluated
(serobiochemical and haematological), urinary 8-iso-PGF2a, respiratory function variables and clinical symptoms of COPD
patients.
Conclusions: Our results suggest that PJ supplementation adds no benefit to the current standard therapy in patients with stable
COPD. The high TEAC of PJ cannot be extrapolated in vivo probably due to the metabolism of its polyphenols by the colonic
microflora. The understanding of the different bioavailability of dietary polyphenols is critical before claiming any antioxidant-
related health benefit.
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Introduction
The 2002 WHO World Health Report (WHO, 2002)
listed chronic obstructive pulmonary disease (COPD)
as the fifth leading cause of death in the world (third
leading cause in adults over 60 years), with increasing
prevalence and mortality in the coming decades (Murray
and Lopez, 1997). According to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD), ‘COPD is a
disease state characterized by airflow limitation that is not
fully reversible. The airflow limitation is usually both
progressive and associated with an abnormal inflammatory
response of the lungs to noxious particles or gases’.
The main aetiologic factor implicated in the pathogenesis
of COPD is smoking (Repine et al., 1997), although air
pollution (Perez-Padilla et al., 1996), occupational exposure
(Vogelzang et al., 1998) and genetic predisposition (Molfino,
2004) are also involved. Cigarette smoke provides a huge
concentration of reactive oxygen species (ROS) that critically
contribute to provoke systemic oxidative stress (Rahman
et al., 1996). Several studies support the role of ROS in the
evolution and pathophysiology of obstructive airway dis-
eases including COPD (Macnee, 2000; Langen et al., 2003;
Molfino, 2004). As oxidative stress is increased in patients
with COPD (Pratico` et al., 1998), antioxidants could be of use
in its treatment. In fact, small but significant reductions in
exacerbations have been reported upon oral administration
of N-acetyl cysteine to patients with this disease (Poole and
Black, 2001). Moreover, various epidemiological and obser-
vational studies demonstrated the positive effect of dietary
antioxidants such as vitamins C and E (Devereux and Seaton,
2001) and some polyphenols from fruits and vegetables
(Tabak et al., 2001; Watson et al., 2002) on the ventilatory
function and clinical manifestations of COPD patients.
However, interventional approaches concerning dietary
antioxidants and COPD are rather scarce (Devereux and
Seaton, 2001). Recently, Culpitt et al. (2003) demonstrated
in vitro the promising use of the polyphenol resveratrol
against COPD.
Among dietary antioxidants, plant polyphenols might
play a major role in human health. Polyphenols have a
number of health-promoting effects including antiplatelet,
antioxidant, anti-inflammatory, antitumoral and oestro-
genic activities, which might suggest their potential in the
prevention and/or amelioration of several diseases including
coronary heart diseases and cancer (Arai et al., 2001; Yang
et al., 2001; Limer and Speirs, 2004). Pomegranate juice (PJ) is
a very rich source of polyphenols, especially ellagitannins
(polymeric molecules with ellagic acid (EA) subunits), EA
derivatives and anthocyanin pigments (Gil et al., 2000).
Pomegranate and derived products have been acknowledged
with health-beneficial effects from ancient times (Madihas-
san, 1984) including hypotensive (Aviram and Dornfeld,
2001), hypocholesterolaemic and antiatherosclerotic activ-
ities (Kaplan et al., 2001). However, the impressing anti-
oxidant activity in vitro of PJ, higher than that of tea and red
wine (Gil et al., 2000), is the main feature that has attracted
attention.
Taking into account the above, the aim of the present
study is to conduct a randomized, double-blind, placebo-
controlled trial to evaluate the effect of daily consumption of
polyphenol-rich PJ with high antioxidant activity for 5
weeks on the oxidative stress and clinical features of patients
with stable COPD.
Subjects and methods
Chemicals
EA, 2,20-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid)
(ABTS), 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic
acid (Troloxt), b-glucuronidase (EC 3.2.1.31; 100 000 units)
from bovine liver and sulphatase (EC 3.1.6.1; 10 000 units)
from Helix pomatia were purchased from Sigma (St Louis, CA,
USA). Methanol, diethyl ether, hydrochloric acid and acetic
acid were obtained from Merck (Darmstadt, Germany).
Ascorbic acid was obtained from Aldrich (Steinheim, Ger-
many). Milli-Q system (Millipore Corp., Bedford, MA, USA)
ultra pure water was used throughout this experiment.
PJ preparation and placebo beverage
PJ was obtained from fresh pomegranates (Punica granatum,
cv Mollar de Albatera) by using a laboratory pilot press
according to Cerda´ et al. (2004). PJ polyphenols were fully
stable under refrigeration and protected from light along the
present study. Polyphenolic content of the juice was
analysed by HPLC–DAD–mass scan (MS)–MS.
Placebo beverage consisted of an orange-flavoured com-
mercial refreshment. The drink contained water, sodium
cyclamate, sodium saccharine, vegetable oil, citric acid,
synthetic orange flavours and stabilizer (Arabic gum) and
lacked antioxidants, fruit and vegetable extracts or vitamins.
Subjects and design
This study conforms to the principles outlined in the
‘Declaration of Helsinki’ and has been approved by the
Committee of Clinical Investigation of the ‘University
Virgen de La Arrixaca Hospital’ (Murcia, Spain). The protocol
was fully explained to the volunteers who gave their written
consent prior to participation.
The inclusion criteria for participating in this trial were
physician-diagnosed COPD, no acute exacerbation of COPD
during 8 weeks before the study and no home oxygeno-
therapy required. Exclusion criteria involved asthma history,
positive prick test, atopy, vegetarian diet, weight-reducing
dietary regimen, alcoholism, consumption of vitamin sup-
plements or nutraceuticals, diabetes, other respiratory
diseases, hyperlipidaemia, history of gastrointestinal disease
or any chronic disease besides COPD. From all COPD
patients recruited to participate in the present trial, 30 men
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with stable COPD and clinical history in the above hospital
were finally enrolled (Table 1). The enrolment of patients in
clinical trials can be sometimes especially difficult. This is
the case of COPD patients whose mean age is over 60 and
display inability to carry out many daily tasks. Both age and
stage of disability of patients affected the design of the study
(urine collection, diet restrictions, intake of juice, etc.).
Patients were randomly distributed in two groups (15
patients each). Both PJ and placebo beverage were supplied
to the patients in the same type of bottle (opaque),
indistinguishable for the volunteers. The drinks were weekly
supplied to both groups. In addition, physicians and
researchers involved in the evaluation of clinical features of
COPD, clinical chemistry and isoprostane analysis did not
know either the type of drink consumed by the patients
(double-blind trial).
The volunteers followed a controlled diet (2 weeks before
and during the 5-week trial) in which ellagitannin-contain-
ing sources such as berries (strawberry, raspberry, blackberry,
etc., and derived foodstuffs such as jams), pomegranates,
chocolate, nuts and wine were strictly forbidden. During
these 7 weeks (2 weeks before and during the 5-week trial),
patients were also asked to consume approximately the same
amount of other polyphenol-containing sources (fruits,
vegetables, tea, coffee, juices and olive oil). The patients
provided a diet history with the food and drinks consumed
along the trial to monitor the intake of specific foodstuffs
that could affect the trial, such as a potential effect on
colonic microflora (probiotics, prebiotics, etc.).
Clinical manifestations and respiratory function variables
were evaluated after the randomized distribution of patients
in both groups prior to the intervention. In addition, urine
and blood samples were taken to determine serobiochemical,
haematological and urinary 8-iso-PGF2a baseline values.
Patients consumed 400 ml of their corresponding drinks
(either PJ or placebo) daily for 5 weeks. Volunteers were free
to consume the juice along the day. Patients attended the
consulting room at the hospital in the morning, the same
day every week (to determine respiratory function variables,
for physical examination and to answer physicians’ ques-
tions regarding the evolution of the trial: possible problems,
accomplishment of the protocol, state of mind, etc.). In
addition, the same morning, blood samples were withdrawn
and patients also provided 12-h urine volume corresponding
to the day before the consultation (i.e. urine sample for the
last 12 h before blood withdrawal). Therefore, in the present
trial, patients were examined six times (once before drinks
supplementation and five times during intervention) and
also provided six samples of both urine and blood (one
baseline and five during intervention).
Assessment and evolution of respiratory function and clinical
symptoms
All the patients were examined before and during the
intervention (as mentioned above). All the patients were
physically examined. Chest X-ray, spirometry and arterial
blood gas determinations were carried out.
Airflow limitation of COPD patients was assessed by
spirometry using a Vitalograph 21.70 spirometer (Bucking-
ham, UK) according to the American Thoracic Society
guidelines (1994). Forced expiratory volume in one second
(FEV1), forced vital capacity (FVC) and FEV1/FVC (FEV1
expressed as a percentage of the FVC, which gives a clinically
useful index of airflow limitation) were determined before
the intervention (baseline values) and once per week along
the study (five determinations) as specified above.
Mean values for partial pressure of arterial oxygen (PaO2)
and arterial carbon dioxide (PaCO2) were determined in an
ABL 520 gas analyser (Radiometer, Denmark).
Plasma samples
Blood was collected in heparinized tubes and processed
according to Cerda´ et al. (2004). The plasma was analysed
by HPLC–DAD–MS–MS. For the enzymatic treatment,
the plasma was treated with both b-glucuronidase and
Table 1 Clinical characteristics of the COPD groups at the beginning of
the triala
Characteristics PJ group
(n¼15)
Placebo group
(n¼15)
Age (year) 60.00710.90 63.4078.90
BMI (kg/m2) 31.4074.80 30.6075.80
PaO2 (mmHg) 72.0278.36 71.84710.46
PaCO2 (mmHg) 40.6374.58 42.3775.50
FEV1 (l) 1.4670.66 0.9370.35
FVC (l) 2.9570.84 2.2170.47
FEV1 (%) 46.00716.01 35.10718.10
FVC (%) 77.02713.68 70.10721.90
FEV1/FVC (%) 46.59711.69 43.24710.73
Gold classification (stage of COPD severity)
Stage I (mild) 0 0
Stage II (moderate) 7 6
Stage III (severe) 6 6
Stage IV (very severe) 2 3
Dyspnoea scoreb
Degree I 4 4
Degree II 7 6
Degree III 4 5
Smoking
Current smokers 1 2
Ex-smokers 14 13
Nonsmokers None None
Infections None None
Therapy
Inhaled b-adrenergic agonists All All
Ipratromium bromide All All
aPatients were randomly distributed in both groups. Plus–minus values are
means7standard deviation.
bAccording to the British Medical Research Council.
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sulphatase as described elsewhere (Cerda´ et al., 2004).
Afterwards, the samples were homogenized with MeOH:0.2 M
HCl (1:1, v:v), vortexed for 30 s and centrifuged at 14 000 g
for 2 min at 41C. The supernatant was filtered through a
0.45mm filter, and analysed by HPLC–DAD–MS–MS.
Urine samples
A volume of 40 ml of urine of each sample provided by the
patients was filtered through a Sep-Pak solid-phase extrac-
tion cartridge (a reverse phase C-18 cartridge; Waters
Millipore, Bedford, MA, USA). The cartridges were previously
activated with 10 ml of MeOH, 10 ml of water and subse-
quently emptied with 10 ml of air. After eluting the sample
volume, the cartridge was washed with 10 ml of water. The
remaining volume in the cartridge was eluted with 2 ml of
MeOH. A sample of 100 ml of the methanolic fraction was
analysed by HPLC–DAD–MS–MS.
HPLC–DAD–MS–MS analysis
The HPLC–DAD system was equipped with a mass detector
from Agilent Technologies (Waldbronn, Germany). The mass
detector was an ion-trap mass spectrometer (Agilent Tech-
nologies) equipped with an electrospray ionization (ESI)
system (capillary voltage 4 kV, dry temperature 3501C) for
the analysis of nonenzymatically treated samples (blood,
urine and PJ). For the analysis of enzyme-treated blood and
urine samples, the mass detector was equipped with an
atmospheric pressure chemical ionization (APCI) system
(capillary voltage 4 kV, dry temperature 3501C, crown voltage
4 kA, APCI temperature 3751C). MS and MS–MS daughter
spectra were measured from m/z 150 up to m/z 500 for urine
and blood samples and from m/z 200 up to m/z 2000 for PJ.
Collision-induced fragmentation experiments were carried
out in the ion trap using helium as the collision gas and the
collision energy was set at 50%. Mass spectrometry data were
acquired in the positive ionization mode for enzyme-treated
samples (with APCI) and in the negative ionization mode for
the juice and nontreated urine and blood samples (with ESI).
Chromatographic separations of PJ and urine samples were
carried out on a reverse-phase C18 LiChroCART column
(250.4 cm, particle size 5 mm, Merck, Darmstadt, Germany)
according to the protocol of Cerda´ et al. (2004).
Quantification of PJ polyphenols and related metabolites
Polyphenols in PJ were identified according to their UV
spectra as well as ion mass (MS), and daughter fragments
(MS–MS) using ion trap (Cerda´ et al., 2004). Anthocyanins
were quantified as cyanidin-3-glucoside at 510 nm (Cerda´
et al., 2004). Identification of EA was carried out by
chromatographic comparisons (UV and MS) with a pure
standard of EA. EA and its glycoside derivatives were
quantified as EA at 360 nm. Punicalagin isomers (the most
abundant ellagitannin in PJ) were quantified at 360 nm using
an external standard of punicalagin previously isolated
(Cerda´ et al., 2003). The in vivo-generated metabolites
derived from pomegranate ellagitannins and EA were
identified according to their UV spectra, retention times,
ion mass and MS–MS daughter fragments using the corre-
sponding purified metabolites previously isolated from hu-
man urine (Cerda´ et al., 2004). The metabolites were
quantified at 305 nm.
Antioxidant assay (ABTSKþ )
ABTSKþ assay was carried out according to Espı´n and
Wichers (2000). In vitro antioxidant activity was expressed
as Trolox Equivalent Antioxidant Capacity (TEAC) following
the nomenclature of Rice-Evans and Miller (1994). Coeffi-
cient of variation was always less than 5%.
Haematological and serobiochemical parameters
Biochemical parameters were determined in serum using an
automated biochemical auto-analyser HITACHI Modular
DþP (Roche Diagnostics, Switzerland). The parameters
analysed were: glucose, urea, creatinine, uric acid, total
proteins, albumin, total bilirubin, cholesterol, HDL-choles-
terol, LDL-cholesterol, triglycerides, alanine aminotransfer-
ase (ALT), aspartate aminotransferase (AST) and ferritin.
Haematological parameters were determined in EDTA-trea-
ted blood using an automated haematological analyser (Cell-
Dyn 3700 and 4000, Abbott, IL, USA). The parameters
analysed were: red blood cells, haemoglobin concentration,
haematocrit, mean corpuscular volume, mean corpuscular
haemoglobin, mean corpuscular haemoglobin concentra-
tion, platelets, mean platelet volume, leucocytes, neutro-
phils, lymphocytes, monocytes, eosinophils and basophils.
Lipidogram
The separation of lipoproteins in human serum was carried
out in agarose gels by using the Paragon Lipoprotein
Electrophoresis Kit (Beckman Instruments Inc., Palo Alto,
CA, USA) according to Cerda´ et al. (2004). The gel was dried
and the lipoprotein pattern visualized by using the Sudan
Black B Stain-containing Paragon Lipo Stain (0.07%; w:w)
(Paragons). Lipidogram allowed determining chylomicrons,
a-lipoprotein, pre-b-lipoprotein and b-lipoprotein.
Urinary isoprostane
The major F2-isoprostane, 8-epi-prostaglandin F2a (also
known as 15-isoprostane F2t, 8-epi-PGF2a or 8-iso-PGF2a),
was measured using a commercially available enzyme-linked
immunoassay (EIA) kit previously validated by manufac-
turers using gas chromatography/mass analysis (GC/MS)
(Oxford Biomedical Research, Oxford, MI, USA). Briefly,
urine samples were mixed with an enhancing reagent
that essentially eliminates interferences due to nonspecific
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binding, and the 8-iso-PGF2a in the samples or standards
competes with 8-iso-PGF2a conjugated to horseradish perox-
idase (HRP) for binding to a polyclonal antibody specific for
8-iso-PGF2a coated on the microplate. The HRP activity
results in colour development when substrate is added, with
the intensity of the colour proportional to the amount of
8-iso-PGF2a bound and inversely proportional to the amount
of unconjugated 8-iso-PGF2a in the samples. Absorbance was
measured at 450 nm in a STAT FAX-2100 spectrophotometer
(Awareness Tech. Inc., Palm City, FL, USA). Urinary 8-iso-
PGF2a values were determined before intervention, at the
third week and at the end of the study (fifth week).
Statistics
Before beginning the experiment, a statistical analysis was
carried out in order to determine the minimum number of
subjects (sample size) required to establish significantly
statistical conclusions. The number of subjects was based
on the construction of a confidence interval (Wonnacott and
Wonnacott, 1990). The required sample size to get a
confidence interval of 95% was determined for each
parameter analysed. Analysis of variance (ANOVA) was used
to establish differences in the PJ and placebo groups upon
consumption of their corresponding drinks (PJ and placebo,
respectively) for 5 weeks. Values are expressed as mean7s.d.
(standard deviation). The normal values range (NVR) estab-
lishes the limit between normal and pathological values for
serobiochemical and haematological parameters. In the
present study, the NVR were those reference values used by
the Hospital’s laboratory. Differences were considered sig-
nificant at Pp0.05. Statistic analyses were carried out with
the SPSS 11.0.1 program (SPSS Inc., Chicago, IL, USA).
Graphs of the experimental data were carried out by using
the Sigma Plott 6.0 program for Windowst.
Results
The PJ used in the present trial was very rich in the polymeric
polyphenols ellagitannins (ETs), especially punicalagin iso-
mers, punicalin, free EA and EA glycosides. In addition, six
anthocyanin pigments were identified as delphinidin,
cyanidin and pelargonidin 3-glucosides and 3,5-digluco-
sides. This juice contained 2.4 g/l punicalagin, 1.97 g/l
punicalin, 0.61 g/l free EA, 0.60 g/l EA-glycosides and
0.49 g/l anthocyanins. This means that the volume of PJ
(400 ml) consumed by COPD patients involved a daily intake
of 2.66 g polyphenols (Table 2). As a whole, COPD patients
received during this trial 93.1 g total polyphenols, including
61.25 g of ETs. Therefore, according to the in vitro antiox-
idant activity of this juice, COPD patients received 4 mmol/l
TEAC daily (equivalent to 2.5 g Trolox/l) and 140 mmol/l
TEAC (87.5 g Trolox/l) after 5 weeks, at the end of the trial.
The absorption and metabolism of PJ polyphenols was
monitored along the trial in the corresponding group that
consumed PJ. Ingested polyphenols (in the molecular form
present in the PJ supplied) were not detected either in
plasma or in urine. However, two EA-derived metabolites,
conjugated with glucuronic acid, that is, 3,8-dihydroxy-6H-
dibenzo(b,d)pyran-6-one (also known as ‘urolithin A’), and
3-hydroxy-6H-dibenzo(b,d)pyran-6-one (‘urolithin B’), were
identified in both plasma and urine of COPD patients
belonging to the PJ group (Figure 1). A high individual
variability was observed in the metabolism of PJ by COPD
patients along the trial (results not shown). This was
supported by previous reports regarding the metabolism of
ellagitannins by humans (Cerda´ et al., 2005) and by the no
relationship between metabolism of PJ polyphenols and the
diet histories provided by the patients (results not shown). At
the end of the 5-week intervention period, a mean
concentration of the above metabolites, 2.0171.6 and
2.472.3 mg/ml, respectively, was detected in urine. No
relation was found (P40.05) between the metabolism of PJ
polyphenols (accumulation of dibenzopyranone metabolites
either in plasma or urine) and age of patients, dyspnoea
score, COPD stage, respiratory function or any other clinical
manifestation associated to COPD.
There were no statistically significant differences in any of
the variables or parameters evaluated (serobiochemical,
haematological, FEV1, FVC, FEV1/FVC, PaCO2, PaO2) within
each group over the 5-week study (Table 3) and thus no
differences were observed either in these values as a
consequence of PJ supplementation when both groups were
compared. No significant differences in any of the variables
or parameters evaluated were found between baseline values
of the two groups (results not shown).
8-Iso-PGF2a values of COPD patients participating in the
present trial, determined with the EIA kit, ranged from 1 to
8.8 pg/mg creatinine in the PJ group and from 1.42 to
8.75 pg/mg creatinine in the placebo group. No relation was
found in COPD patients between urinary isoprostane
concentration and any of the above parameters evaluated.
Mean 8-iso-PGF2a values did not significantly change in both
PJ and placebo groups over the 5-week period (P40.05)
(Table 3).
Table 2 Polyphenol content and TEAC of PJ consumed by COPD
patientsa
Polyphenols and TEAC Per day (volume:
400 ml)
Over 5 weeks (total
volume: 14 l)
Ellagitannins
Punicalagin isomers (g) 0.96 33.60
Punicalin (g) 0.79 27.65
EA-glycoside derivatives (g) 0.48 16.80
Free EA (g) 0.24 8.40
Total anthocyanins (g) 0.19 6.65
Total polyphenols (g) 2.66 93.1
TEAC (mmol/l) 4 140
aUsing the ABTS method and according to the nomenclature of Rice-Evans
and Miller.
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Although no effect was observed in any of the parameters
or variables evaluated upon PJ supplementation, some
patients declared in the weekly attendance to the consulta-
tion an improvement in their ability to carry out daily tasks.
However, these patients belonged to both groups and thus it
was an evident ‘placebo effect’.
Discussion
PJ has been acknowledged as one of the most antioxidant
foodstuffs described so far, with antioxidant capacity in vitro
about three-fold higher than that of well-known antioxidant
beverages such as tea or red wine (Gil et al., 2000). PJ owes its
impressive in vitro antioxidant activity to its polyphenolic
constituents, especially to ellagitannins (ETs), very abundant
in PJ (Gil et al., 2000). A recent study reported that the
supplementation of 1 l of PJ to healthy subjects for 5 days
had no effect either on plasma antioxidant status or
cardiovascular risk markers (Cerda´ et al., 2004). However,
the effect of a longer PJ supplementation in subjects with
unbalance oxidative status remained unanswered so far.
Therefore, the present trial was conducted to investigate
whether polyphenol-rich PJ (with high TEAC) could amelio-
rate the systemic oxidative stress of COPD patients as a
potential dietary complement to standard therapy.
Despite the high daily TEAC (4 mmol/l) provided to the
COPD patients who consumed PJ (Table 2), no effect was
observed in any serobiochemical and haematological para-
meter or respiratory function variables (Table 3). Our
possible hypothesis to explain this lack of effect is the
metabolism of the major antioxidant fraction of PJ, the
polyphenols ellagitannins, by the colonic microflora of
COPD patients to yield two bioavailable dibenzopyranone
derivatives with negligible antioxidant activity as recently
reported in the aforementioned report that described the
supplementation of PJ in healthy subjects (Cerda´ et al.,
2004). In fact, these dibenzopyranone derivatives have been
proposed as biomarkers of human exposure to ellagitannins
and EA (Cerda´ et al., 2005).
Although the ‘ideal’ biomarker to measure oxidative
damage does not exist, F2-isoprostane is one of the most
widely accepted biomarkers to determine lipid peroxidation
in vivo (Halliwell and Whiteman, 2004). In fact, F2-isopros-
tanes (8-Iso-PGF2a) have been proposed as potential in vivo
indicators of oxidative stress in various clinical conditions
(Pratico` et al., 1998, 1999; Proudfott et al., 1999). 8-Iso-PGF2a
of healthy subjects range from 0.27 to 3.5 pg/mg creatinine
(determined with EIA) (Engler et al., 2004). These values are
usually increased in COPD patients (Pratico` et al., 1998) since
reactive oxygen species (ROS) are involved in the evolution
and pathophysiology of this disease (Langen et al., 2003).
Data regarding the effect of polyphenol antioxidants on
isoprostane concentration are apparently contradictory in
the literature. For example, lack of effect has been described
for polyphenols from chocolate (O¨ner-Iyidogan et al., 2004),
red wine (Waddington et al., 2004), onions and black tea
(O’Reilly et al., 2001). However, decrease of isoprostanes
upon polyphenol intake has been reported for soy (Wiseman
et al., 2000) and also for cocoa polyphenols (Wiswedel et al.,
2004).
In the present trial, PJ supplementation did not signifi-
cantly alter the urinary 8-iso-PGF2a concentration in COPD
patients (Table 3). Therefore, the high potential antioxidant
activity ingested by COPD patients belonging to the PJ group
(4 mM TEAC) had no effect on systemic oxidative stress of
COPD patients, supporting the lack of effect on any
respiratory function variable evaluated (Table 3). In the case
of lung obstructive diseases such as COPD, the bioavailability
of dietary antioxidants to reach lung airways is critical
(Barnes and Hansel, 2004). However, no bioavailable poly-
phenol antioxidants (in the molecular form present in PJ)
that could reach lung airways were detected in COPD
patients.
Our results suggests that daily supplementation of poly-
phenol-rich PJ (with high TEAC) is not promising as possible
dietary supplement to ameliorate the oxidative stress
Figure 1 Representative HPLC profiles of plasma (a) and urine (b)
of a COPD patient upon PJ consumption after 1 week. (1) Urolithin
A-glucuronide: 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one glucur-
onide (m/z¼404; MS/MS¼175, 227), (2) Urolithin B-glucuronide:
3-hydroxy-6H-dibenzo(b,d)pyran-6-one glucuronide (m/z¼389;
MS/MS¼175, 213).
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associated to COPD pathophysiology. In vitro antioxidant
activity of PJ has been reported previously (Gil et al., 2000;
Noda et al., 2002; Singh et al., 2002) and the antiatherogenic
and atherosclerotic effects of PJ have been attributed to its
antioxidant properties (Aviram et al., 2000). However, the
present trial, together with our recent report regarding the
supplementation of PJ on healthy subjects (Cerda´ et al.,
2004), critically questions that the potential health benefits
of PJ are mediated by its antioxidant activity. Regardless of
the not yet well-established relationship between in vitro
antioxidant capacity and health benefits of PJ, other health-
promoting effects of PJ, beyond antioxidant activity, cannot
be discarded as suggested already for other polyphenolic-rich
foodstuffs (Waddington et al., 2004). Whether longer
supplementation periods (months or years) with PJ may
have some beneficial effects on COPD patients cannot be
ruled out and has not been approached in this trial. In fact,
from a dietary point of view, a preventive (chronic) rather
than therapeutic (acute) effect should be expected for dietary
phytochemical-rich foodstuffs.
Very recently (coincident with the submission of the
present study), the decrease of urinary isoprostanes (up to
50%) in COPD patients upon consumption of polyphenol-
enriched grape extracts (0.5 g polyphenols daily) for 40 days
has been reported (Santus et al., 2005). Although this study
was not placebo-controlled, the diet of COPD patients
(n¼11) was not controlled and polyphenolic analysis as
well as absorption and metabolism studies were not carried
out; however, the impressing decrease of isoprostanes
described together with the improvement of ventilatory
functions in COPD patients confirms our hypothesis regard-
ing the critical relationship between the bioavailability and
bioactivity of polyphenols. Therefore, our results support
previous investigations suggesting that the in vitro antiox-
idant activity of dietary phytochemicals such as polyphenols
does not seem to be a valid ‘health-promoting index’ with
direct extrapolation in vivo. This will depend on the specific
bioavailability and metabolism of each polyphenol. In this
context, studies on absorption, metabolism and fate of both
ingested phytochemicals and in vivo-generated metabolites
for each phytochemical-rich foodstuff should precede any
antioxidant health claim.
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Table 3 Differences in parameters and variables evaluated in COPD patients over 5 weeks in the PJ and placebo groupsa,b
Parameters PJ group Placebo group
Baseline 5 weeks P-value Baseline 5 weeks P-value
Glucose (mg/dl) 114.46725.53 120.80740.30 0.54 113.73751.53 116.40753.60 0.98
Urea (mg/dl) 38.6279.95 36.70711.10 0.74 36.4579.67 34.1078.60 0.24
Creatinine (mg/dl) 0.9470.19 0.9770.20 0.53 0.8970.20 0.9270.21 0.61
Uric acid (mg/dl) 6.4071.10 6.5071.15 0.45 5.8371.81 5.9071.81 0.89
Total proteins (g/dl) 7.0670.51 7.0970.52 0.62 6.9570.42 6.9770.39 0.85
Albumin (g/dl) 4.3870.28 4.4970.28 0.57 4.3870.13 4.4370.21 0.32
Total bilirubin (mg/dl) 0.6370.33 0.5870.26 0.63 0.5670.21 0.5570.23 0.81
Cholesterol (mg/dl) 205.54744.89 209.68739.10 0.83 197.45733.79 201.34732.64 0.89
Triacylglycerols (mg/dl) 157.857210.63 170.687187.10 0.98 127.55751.03 137.91778.22 0.66
HDL (mg/dl) 56.67713.72 55.05712.01 0.39 56.09722.59 56.75720.81 0.93
LDL (mg/dl) 127.00739.14 130.48732.29 0.43 115.91727.46 116.06729.14 0.77
GOT (U/l) 18.5475.01 21.92710.97 0.16 21.2778.22 21.3778.39 0.88
GPT (U/l) 20.00713.32 26.59718.46 0.12 20.1079.46 20.5379.99 0.98
Ferritin (ng/ml) 234.087182.18 280.047210.44 0.82 132.9794.83 127.47791.71 0.85
Chylomicrons (%) 0.7570.63 1.0971.25 0.24 1.0871.37 0.8770.93 0.88
a-Lipoprotein (%) 28.7278.79 27.0277.66 0.32 27.5176.54 28.7078.25 0.45
Pre-b-lipoprotein (%) 22.89714.47 25.82713.70 0.25 26.85711.71 25.6679.47 0.95
b-Lipoprotein (%) 46.85710.07 45.56710.33 0.29 44.5078.39 44.2978.67 0.55
Isoprostane (pg/mg creatinine) 4.4672.37 4.5072.97 0.49 4.7072.87 4.4172.97 0.44
FEV1 (l) 1.4670.66 1.3870.61 0.74 0.9370.36 0.9170.43 0.92
FVC (l) 2.9570.84 2.9470.76 0.97 2.2170.47 2.0370.48 0.39
FEV1/FVC (%) 46.60711.70 45.60713.28 0.84 43.24710.73 44.1712.91 0.44
PaO2 (mmHg) 72.0278.36 72.1978.70 0.96 71.84710.46 71.6779.98 0.97
PaCO2 (mmHg) 40.6374.58 40.3574.66 0.88 42.3775.50 42.5075.26 0.95
aHaematological parameters are not shown (P40.05 for all values).
bThe NVR for serobiochemical parameters were those reference values used by the Hospital’s laboratory: glucose 76–110 mg/dl; urea 10–50 mg/dl; creatinine 0.7–
1.3 mg/dl; uric acid 3.4–7 mg/dl; total proteins 6.6–8.7 g/l; albumin 3.5–5.3 g/l; total bilirubin 0.1–1.1 g/l; cholesterol 50–230 mg/dl; triacylglycerols 50–200 mg/dl;
HDL 45–75 mg/dl; LDLo130 mg/dl; GOT 5–37 U/l; GPT 5–40 U/l; ferritin 30–400 ng/ml; chylomicrons 0–2%; a-lipoprotein 9.8–46.2%; pre-b-lipoprotein 0–29.6%;
b-lipoprotein 40.7–71.9%.
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